Home › Endometrial Cancer › Ohio › Cincinnati
Endometrial Cancer clinical trials in Cincinnati, OH
14 studies for Endometrial Cancer are looking for participants at sites in and around Cincinnati (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- Good Samaritan Hospital - Cincinnati, Cincinnati
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
RecruitingPhase 3
- University of Cincinnati Medical Center ( Site 5013), Cincinnati
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
RecruitingPhase 3
- University of Cincinnati Medical Center, Cincinnati
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RecruitingPhase 1
- St. Elizabeth Healthcare, Edgewood · 8 mi away
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
RecruitingPhase 3
- University of Cincinnati Physicians Group, LLC, Cincinnati
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Oncology Hematology Care Primary, Cincinnati
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RecruitingPhase 3
- Research Site, Cincinnati
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
RecruitingPhase 2
- Research Site, Cincinnati
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingPhase 1/2
- Cincinnati Children's Hospital Medical Center, Cincinnati
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
RecruitingPhase 2
- University of Cincinnati Cancer Center, Cincinnati
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RecruitingPhase 3
- Research Site, Cincinnati
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RecruitingPhase 2
- University of Cincinnati Medical Center, Cincinnati
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
RecruitingPhase 1/2
- The Christ Hospital, Cincinnati
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Cincinnati
Endometrial Cancer trials in other cities
- Houston, TX69 studies
- New York City, NY54 studies
- Boston, MA51 studies
- Arlington, VA41 studies
- Nashville, TN38 studies
- Los Angeles, CA35 studies
- St. Louis, MO29 studies
- Philadelphia, PA29 studies
- Oklahoma City, OK28 studies
- San Antonio, TX27 studies
- Queens, NY26 studies
- Dallas, TX25 studies
Other studies in Cincinnati
- Non-Small Cell Lung Cancer31 studies
- Cancer (all types)26 studies
- Breast Cancer24 studies
- Heart Failure22 studies
- Metastatic Cancer21 studies
- Colorectal Cancer20 studies
- Obesity20 studies
- Acute Myeloid Leukemia20 studies
- Prostate Cancer19 studies
- Ovarian Cancer18 studies
- Lung Cancer18 studies
- Multiple Myeloma17 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.